Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts at TechBio UK 2024, an event run by the BioIndustry Association (BIA).
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the evolving landscape.
From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved out an exciting and unconventional career in science.
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization of innovative cellular therapies.
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025).
Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity with undisclosed investments in its small molecule offerings.
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
Patient recruitment is a critical and often challenging aspect of clinical trials, particularly for biopharmaceutical companies seeking to accelerate drug development.
Rebekah's father passed on his passion for science and problem solving to her and much of her childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.
At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch of a state-of-the-art nanomedicines GMP facility in Oss, Netherlands.
As CPHI Milan 2024 approaches, Symbiosis Pharmaceutical Services is gearing up to showcase major expansions and innovations in sterile biopharmaceutical manufacturing.
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
The company will introduce its innovative siliconized moulded glass vials, positioning itself as the only global supplier offering this technology to pharmaceutical standards.
Artificial intelligence has emerged as a potential solution to inconsistent reporting of adverse events, which to this day remains one of the main challenges in the field of pharmacovigilance.
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.
Joaquima Guix Salichs is the director of engineering and extraction technology at Bioiberica, where she leads a team of scientists focused on advancing extraction methods and solving large-scale industrial challenges.
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions.
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions.
Recent investments by major pharmaceutical companies signal a growing confidence in artificial intelligence’s (AI's) potential to transform drug development.
As local and state governments in the US begin to receive and distribute their opioid settlement funds, Sonara Health has developed a comprehensive report analyzing how over $50 billion in national funds can be effectively allocated to address the opioid...
Phastar have implemented an RBQM app within their Clinical Intelligence Data Visualisation Platform, enabling a comprehensive overview of the entire trial across all sites which can be shown in various visualisation graphs, tailored by client.
CluePoints, the leading provider of risk-based quality management (RBQM) and data quality oversight software, has announced the full agenda and speaker line-up for the highly anticipated RBQMLive 2024.
The European Organisation for Research and Treatment of Cancer (EORTC) has renewed and extended its partnership with Medidata, a provider of clinical trial solutions for the life sciences industry.
Slope, a global provider of biospecimen lifecycle software, data, and services for clinical trials, has announced the launch of a new suite of premium services designed to optimize biospecimen operations and data management.
Envision Pharma Group, a global leader in technology solutions for the life sciences industry, has unveiled its latest innovation, EnvisionOne Insights.
